Publication | Open Access

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial

Breast OncologyMedicineImmunologyClinical TrialsSecondary OutcomesBreast CancerPharmacotherapyAdjuvant BevacizumabCancer TreatmentOncologyPhase 3